Thierry Hulot – President Biopharma, Merck France

Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also shares insights into his career and the learnings from the Levothyrox case.  
Overall, we are a very important branch of the Merck group and we have a positive impact on the French economy, with significant investments in this country
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In

Related Interviews

Latest Report